ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1350

Inflammatory Biomarkers in Psoriatic Arthritis

Ibrahim AlHomood1, Arane Thavaneswaran1, D. D. Gladman2 and Vinod Chandran3, 1Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 2Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, 3Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Biomarkers and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment

Session Type: Abstract Submissions (ACR)

Background/Purpose:  Psoriatic arthritis (PsA) is an inflammatory arthritis that may progress rapidly and result in joint damage and disability. The aim of this study was to establish the frequency of raised inflammatory markers (ESR and CRP) in PsA and to investigate their association with disease activity and progression.

Methods: At the PsA Clinic patients are followed prospectively and are evaluated according to a standard protocol which includes a detailed clinical history, physical examination, laboratory and radiological assessments every 6 –12 months.ESR levels are recorded as normal or raised (15 mm/hour for male patients, 20 mm/hour for female patients) as well as CRP as normal or raised (0-3). X-rays are done every two years. Patients followed between 2006 and 2011 were included.

ESR and CRP were measured at baseline in all patients included in this study, and correlated with other disease features at baseline. Pearson correlation coefficient was used for correlations between the continuous variables. We also constructed univariate and multivariate models based on information at baseline to detect the variables that associate with disease activity and severity. The covariates were age at onset of PsA, sex, duration of PsA, use of biologics, infection and BMI.

Results:   A total of 253 patients with PsA (107 male and 146 female with mean duration of PsA 5.2±7.6 years) were included.ESR level ranged from 0 to 121 mm/hr at baseline. Mean ESR was 18.3±21.2 (median 11) and was elevated in 28.1%. CRP level ranged from 3 to 132 mg/l. Mean CRP was 14.3±20.7 (median 5) mg/l and was elevated in 54.9%.

 Correlation between ESR and CRP with the variables

 

Active joint count

Damaged joint count

BASDAI

PASI

 

Correlation

P-value

Correlation

P-value

Correlation

P-value

Correlation

P-value

ESR

0.14

P=0.02

0.16

P=0.01

0.17

P=0.05

0.23

P=0.0004

CRP

0.07

P=0.26

0.03

P=0.63

0.23

P=0.008

0.31

P<0.0001

The association between ESR and CRP and different variables

 

ESR

CRP

variable

Univariate analysis

p-value

Multivariate linear regression     p-value

Univariate analysis  p-value

Multivariate linear regression     p-value

Active joints

0.02

0.006

0.26

0.67

Damage joints

0.01

0.07

0.63

0.32

PASI

0.0004

0.004

<0.0001

0.13

BASDI

0.05

0.28

0.008

0.30

Radiological damage

0.12

0.68

0.04

0.16

 Conclusion: Increased ESR was observed in 28.1% of PsA and was correlated with active and damaged joint count and PASI. Increased CRP was observed in 54.9% of PsA and was correlated with PASI. Inflammatory markers are associated with disease activity and progression.

 


Disclosure:

I. AlHomood,
None;

A. Thavaneswaran,
None;

D. D. Gladman,
None;

V. Chandran,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/inflammatory-biomarkers-in-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology